Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
September 30, 2026 43.39M
June 30, 2026 21.73M
March 31, 2026 21.78M
December 31, 2025 21.09M
September 30, 2025 20.63M
June 30, 2025 0.229M
March 31, 2025 0.278M
December 31, 2024 0.286M
September 30, 2024 0.254M
June 30, 2024 0.753M
March 31, 2024 0.987M
December 31, 2023 1.515M
September 30, 2023 2.667M
June 30, 2023 3.501M
March 31, 2023 13.38M
December 31, 2022 22.55M
September 30, 2022 31.83M
Date Value
June 30, 2022 37.45M
March 31, 2022 39.29M
December 31, 2021 37.64M
September 30, 2021 39.27M
June 30, 2021 45.94M
March 31, 2021 47.68M
December 31, 2020 56.41M
September 30, 2020 65.00M
June 30, 2020 73.60M
March 31, 2020 85.56M
December 31, 2019 94.66M
September 30, 2019 96.43M
June 30, 2019 95.63M
March 31, 2019 92.13M
December 31, 2018 87.72M
September 30, 2018 89.63M
June 30, 2018 88.97M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Q32 Bio, Inc. 15.94M
IRulya Therapeutics, Inc. 30.76M
Climb Bio, Inc. 43.60M
PepGen Inc. 52.70M
Bridgebio Oncology Therapeutics, Inc. 156.69M